Strata

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 171318 Experts worldwide ranked by ideXlab platform

Raphael Rubin - One of the best experts on this subject based on the ideXlab platform.

  • A randomized, double-blind, placebo-controlled trial of ursodeoxycolic acid in primary biliary cirrhosis. Hepatology
    2016
    Co-Authors: Burton Combes, Robert L. Carithers, Willis C. Maddrey, Danyu Lin, Mary F. Mcdonald, Donald E. Wheeler, Edwin H. Eigenbrodt, Santiago G. Mu~oz, Raphael Rubin, Guadalupe Garcia-tsao
    Abstract:

    One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four Strata based on entry serum bilirubin (<2 mg/dL vs. 2 mg/dL or greater) and liver histology (stages I, II vs. stages III, IV--Ludwig criteria) were randomized within each stratum to urso-diol or placebo given in a single dose of 10 to 12 mg/kg at bedtime for 2 years. Placebo- (n = 74) and ursodiol-treated (n = 77) patients were well matched at baseline for demographic and prognostic factors. Ursodiol in-duced major improvements in biochemical tests of the liver in Strata 1 and 2 (entry bilirubin ~2), but had less effect on laboratory tests in patients with entry serum bilirubin of->2 (Strata 3 and 4). Histology was favorably affected by ursodiol in patients in Strata I and 2 but not in Strata 3 and 4. Ursodiol enrichment in fasting bil

  • a randomized double blind placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
    Hepatology, 1993
    Co-Authors: Burton Combes, Robert L. Carithers, Willis C. Maddrey, Mary F. Mcdonald, Donald E. Wheeler, Edwin H. Eigenbrodt, D Y Lin, Santiago J Munoz, Raphael Rubin
    Abstract:

    One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four Strata based on entry serum bilirubin ( or +2 (Strata 3 and 4). Histology was favorably affected by ursodiol in patients in Strata 1 and 2 but not in Strata 3 and 4. Ursodiol enrichment in fasting bile obtained at the conclusion of the trail was approximately 40% and comparable in all Strata. Thus, differences in ursodiol enrichment of the bile acid pool do not explain better responses of laboratory tests and histology found in patients with less advanced PBC. Patients treated will ursodiol tended to develop a treatment failure less frequently that those who received placebo, particularly in Strata 1 and 2 (ursodiol 42%, placebo 60%, P = .078). Development of severe symptoms (fatigue/pruritus) and doubling of serum bilirubin were reduced significantly in ursodiol-treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Willis C. Maddrey - One of the best experts on this subject based on the ideXlab platform.

  • A randomized, double-blind, placebo-controlled trial of ursodeoxycolic acid in primary biliary cirrhosis. Hepatology
    2016
    Co-Authors: Burton Combes, Robert L. Carithers, Willis C. Maddrey, Danyu Lin, Mary F. Mcdonald, Donald E. Wheeler, Edwin H. Eigenbrodt, Santiago G. Mu~oz, Raphael Rubin, Guadalupe Garcia-tsao
    Abstract:

    One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four Strata based on entry serum bilirubin (<2 mg/dL vs. 2 mg/dL or greater) and liver histology (stages I, II vs. stages III, IV--Ludwig criteria) were randomized within each stratum to urso-diol or placebo given in a single dose of 10 to 12 mg/kg at bedtime for 2 years. Placebo- (n = 74) and ursodiol-treated (n = 77) patients were well matched at baseline for demographic and prognostic factors. Ursodiol in-duced major improvements in biochemical tests of the liver in Strata 1 and 2 (entry bilirubin ~2), but had less effect on laboratory tests in patients with entry serum bilirubin of->2 (Strata 3 and 4). Histology was favorably affected by ursodiol in patients in Strata I and 2 but not in Strata 3 and 4. Ursodiol enrichment in fasting bil

  • a randomized double blind placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
    Hepatology, 1993
    Co-Authors: Burton Combes, Robert L. Carithers, Willis C. Maddrey, Mary F. Mcdonald, Donald E. Wheeler, Edwin H. Eigenbrodt, D Y Lin, Santiago J Munoz, Raphael Rubin
    Abstract:

    One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four Strata based on entry serum bilirubin ( or +2 (Strata 3 and 4). Histology was favorably affected by ursodiol in patients in Strata 1 and 2 but not in Strata 3 and 4. Ursodiol enrichment in fasting bile obtained at the conclusion of the trail was approximately 40% and comparable in all Strata. Thus, differences in ursodiol enrichment of the bile acid pool do not explain better responses of laboratory tests and histology found in patients with less advanced PBC. Patients treated will ursodiol tended to develop a treatment failure less frequently that those who received placebo, particularly in Strata 1 and 2 (ursodiol 42%, placebo 60%, P = .078). Development of severe symptoms (fatigue/pruritus) and doubling of serum bilirubin were reduced significantly in ursodiol-treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Burton Combes - One of the best experts on this subject based on the ideXlab platform.

  • A randomized, double-blind, placebo-controlled trial of ursodeoxycolic acid in primary biliary cirrhosis. Hepatology
    2016
    Co-Authors: Burton Combes, Robert L. Carithers, Willis C. Maddrey, Danyu Lin, Mary F. Mcdonald, Donald E. Wheeler, Edwin H. Eigenbrodt, Santiago G. Mu~oz, Raphael Rubin, Guadalupe Garcia-tsao
    Abstract:

    One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four Strata based on entry serum bilirubin (<2 mg/dL vs. 2 mg/dL or greater) and liver histology (stages I, II vs. stages III, IV--Ludwig criteria) were randomized within each stratum to urso-diol or placebo given in a single dose of 10 to 12 mg/kg at bedtime for 2 years. Placebo- (n = 74) and ursodiol-treated (n = 77) patients were well matched at baseline for demographic and prognostic factors. Ursodiol in-duced major improvements in biochemical tests of the liver in Strata 1 and 2 (entry bilirubin ~2), but had less effect on laboratory tests in patients with entry serum bilirubin of->2 (Strata 3 and 4). Histology was favorably affected by ursodiol in patients in Strata I and 2 but not in Strata 3 and 4. Ursodiol enrichment in fasting bil

  • a randomized double blind placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
    Hepatology, 1993
    Co-Authors: Burton Combes, Robert L. Carithers, Willis C. Maddrey, Mary F. Mcdonald, Donald E. Wheeler, Edwin H. Eigenbrodt, D Y Lin, Santiago J Munoz, Raphael Rubin
    Abstract:

    One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four Strata based on entry serum bilirubin ( or +2 (Strata 3 and 4). Histology was favorably affected by ursodiol in patients in Strata 1 and 2 but not in Strata 3 and 4. Ursodiol enrichment in fasting bile obtained at the conclusion of the trail was approximately 40% and comparable in all Strata. Thus, differences in ursodiol enrichment of the bile acid pool do not explain better responses of laboratory tests and histology found in patients with less advanced PBC. Patients treated will ursodiol tended to develop a treatment failure less frequently that those who received placebo, particularly in Strata 1 and 2 (ursodiol 42%, placebo 60%, P = .078). Development of severe symptoms (fatigue/pruritus) and doubling of serum bilirubin were reduced significantly in ursodiol-treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Shun Liang - One of the best experts on this subject based on the ideXlab platform.

  • key Strata characteristics controlling the integrity of deep wells in longwall mining areas
    International Journal of Coal Geology, 2017
    Co-Authors: Shun Liang, Derek Elsworth, Xuehua Li, Xuehai Fu
    Abstract:

    Abstract The damage of vertical oil/gas wells in longwall mining areas is mainly a result of Strata movement induced by coal extraction. Strata with contrasting lithology vary dramatically in their movement and potential for well damage, with some special combinations of Strata in particular having the greatest potential for damage. This study investigates the effects of specific combinations of Strata transition structures ((i) topsoil-bedrock, (ii) a thin weak interlayer sandwiched above and below by two stiff beds, and (iii) the key-stratum sandwiched above and below by two soft beds) on the magnitude, severity and distribution of various anticipated well deformations, and explores the optimal drilling path for wells to maximize well integrity. Results indicate that: (1) Effects of various combinations of Strata on well deformation lie essentially in the mismatch in the mechanical properties of the Strata and weak interfaces, with the stratum thickness and vertical distance from the coal seam to the stratum/interface also exerting a significant influence. (2) Wells in the upper part of the topsoil are subject to horizontal tension, while the lower part is laterally compressed following the extraction of either one panel or both panels. Large lateral tensile strains normally arise at the upper part of the hard Strata which directly underlie the soft Strata. Large lateral compressive strains are concentrated in the Strata within ~ 5 m above and below the coal seam and peak in the seam. Longitudinal well deformation is dominated by compression in soft Strata, especially in the upper part of the layer, and is dominated by tension in stiff Strata, within the lower portion in particular. Vertical compression at the interface is larger below the key-stratum, and peaks at the interface between the coal seam and its immediate roof. Well distortions in soft Strata are 3 to 5 times those of ones in stiff Strata. (3) Well deformations developing both at interfaces and within layers significantly intensify in the vicinity of the seam. An integrated consideration of various deformations of five candidate well paths indicates that the optimal position for well stability is the one that deviates from the pillar centerline and is close to the second mined panel.

Edwin H. Eigenbrodt - One of the best experts on this subject based on the ideXlab platform.

  • A randomized, double-blind, placebo-controlled trial of ursodeoxycolic acid in primary biliary cirrhosis. Hepatology
    2016
    Co-Authors: Burton Combes, Robert L. Carithers, Willis C. Maddrey, Danyu Lin, Mary F. Mcdonald, Donald E. Wheeler, Edwin H. Eigenbrodt, Santiago G. Mu~oz, Raphael Rubin, Guadalupe Garcia-tsao
    Abstract:

    One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four Strata based on entry serum bilirubin (<2 mg/dL vs. 2 mg/dL or greater) and liver histology (stages I, II vs. stages III, IV--Ludwig criteria) were randomized within each stratum to urso-diol or placebo given in a single dose of 10 to 12 mg/kg at bedtime for 2 years. Placebo- (n = 74) and ursodiol-treated (n = 77) patients were well matched at baseline for demographic and prognostic factors. Ursodiol in-duced major improvements in biochemical tests of the liver in Strata 1 and 2 (entry bilirubin ~2), but had less effect on laboratory tests in patients with entry serum bilirubin of->2 (Strata 3 and 4). Histology was favorably affected by ursodiol in patients in Strata I and 2 but not in Strata 3 and 4. Ursodiol enrichment in fasting bil

  • a randomized double blind placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
    Hepatology, 1993
    Co-Authors: Burton Combes, Robert L. Carithers, Willis C. Maddrey, Mary F. Mcdonald, Donald E. Wheeler, Edwin H. Eigenbrodt, D Y Lin, Santiago J Munoz, Raphael Rubin
    Abstract:

    One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four Strata based on entry serum bilirubin ( or +2 (Strata 3 and 4). Histology was favorably affected by ursodiol in patients in Strata 1 and 2 but not in Strata 3 and 4. Ursodiol enrichment in fasting bile obtained at the conclusion of the trail was approximately 40% and comparable in all Strata. Thus, differences in ursodiol enrichment of the bile acid pool do not explain better responses of laboratory tests and histology found in patients with less advanced PBC. Patients treated will ursodiol tended to develop a treatment failure less frequently that those who received placebo, particularly in Strata 1 and 2 (ursodiol 42%, placebo 60%, P = .078). Development of severe symptoms (fatigue/pruritus) and doubling of serum bilirubin were reduced significantly in ursodiol-treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Strata - 15 days free trial to Access Experts & Abstracts